StockData
Aldeyra Therapeutics, Inc. logo

Aldeyra Therapeutics, Inc. (ALDX) stock

ALDXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/30
$0.84+0.12 (+16.39%)

Close on Nov 20, 2026Market cap $50.67MP/E –Yield –

Aldeyra Therapeutics free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Aldeyra Therapeutics's free cash flow for the twelve months ending Dec 31, 2023 was -$30.33M. For fiscal 2023 it was -$30.33M. The highest annual figure on record is -$4.79M in fiscal 2014.

Annual free cash flow

PeriodPeriod endValueChange
FY2023Dec 31, 2023-$30.33M–
FY2022Dec 31, 2022-$56.65M–
FY2021Dec 31, 2021-$42.56M–
FY2019Dec 31, 2019-$44.99M–
FY2018Dec 31, 2018-$30.12M–
FY2017Dec 31, 2017-$19.25M–
FY2016Dec 31, 2016-$15.16M–
FY2015Dec 31, 2015-$9.40M–
FY2014Dec 31, 2014-$4.79M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2023Dec 31, 2023$500.44K–
Q3 FY2023Sep 30, 2023-$8.02M–
Q2 FY2023Jun 30, 2023-$13.36M–
Q1 FY2023Mar 31, 2023-$9.44M–
Q4 FY2022Dec 31, 2022-$11.23M–
Q3 FY2022Sep 30, 2022-$12.57M–
Q2 FY2022Jun 30, 2022-$19.96M–
Q1 FY2022Mar 31, 2022-$12.89M–
Q4 FY2021Dec 31, 2021-$11.58M–
Q3 FY2021Sep 30, 2021-$8.43M–
Q2 FY2021Jun 30, 2021-$9.07M–
Q1 FY2021Mar 31, 2021-$13.48M–
Q3 FY2020Sep 30, 2020-$6.24M–
Q4 FY2019Dec 31, 2019-$11.23M–
Q3 FY2019Sep 30, 2019-$8.32M–
Q2 FY2019Jun 30, 2019-$12.82M–
Q1 FY2019Mar 31, 2019-$12.64M–
Q4 FY2018Dec 31, 2018-$7.98M–
Q3 FY2018Sep 30, 2018-$7.74M–
Q4 FY2017Dec 31, 2017-$5.03M–
Q3 FY2017Sep 30, 2017-$4.71M–
Q2 FY2017Jun 30, 2017-$5.31M–
Q1 FY2017Mar 31, 2017-$4.20M–
Q4 FY2016Dec 31, 2016-$3.91M–
Q3 FY2016Sep 30, 2016-$3.50M–
Q2 FY2016Jun 30, 2016-$3.26M–

More Aldeyra Therapeutics figures

See a number that looks wrong?